NET PROFIT (x1000 SEK)
NeoProteomics AB
Closing information (x1000 SEK)
| Closing information | 2022/12 | 2021/12 | 2020/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
48
|
48
|
47 |
| Earnings before taxes |
-114
|
-66
|
-258 |
| EBITDA |
-66
|
-19
|
-212 |
| Total assets |
5,779
|
5,682
|
5,701 |
| Current assets |
112
|
25
|
44 |
| Current liabilities |
4,447
|
4,312
|
4,265 |
| Equity capital |
1,332
|
1,370
|
1,436 |
| - share capital |
110
|
110
|
110 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2022/12 | 2021/12 | 2020/12 |
| Solvency |
23.0%
|
24.1%
|
25.2% |
| Turnover per employee | |||
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-1.1%
|
-0.3%
|
-3.7% |
| Current ratio |
2.5%
|
0.6%
|
1.0% |
| Return on equity (ROE) |
-8.6%
|
-4.8%
|
-18.0% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
0
|
-2 |
| Chg. No. of employees % | -100% |
Total value of public sale
| Fiscal year | 2022/12 | 2021/12 | 2020/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.